Payer strategy applies at all stages of the drug development process. We have helped clients from start-up to launch.
Start-up: investors want to understand the opportunity for access and utilization of new products. Is this a product for Medicare? Commercial?
Early Clinical Phase: will this pharmaceutical be accessed via medical or pharmacy benefits, what is the difference and why will it matter? Is there an opportunity to influence this decision?
Phase II to III transition: what data will be required by payers? How can you answer their requests for relevant clinical and economic information while pursuing the path set out by the FDA and EMA?
Dialog with Payers
Advisory boards, panels, and interviews are just some of the means we use to obtain information and advice from payers. This information informs and propels strategy so that you are ready for P&T Committee meetings, Health Technology Assessment activities. and Clinical Policy discussions